{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:56:25Z","timestamp":1776329785103,"version":"3.50.1"},"reference-count":20,"publisher":"Baskent University","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2019,5,28]]},"DOI":"10.6002\/ect.2018.0027","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T02:50:14Z","timestamp":1552618214000},"page":"326-329","source":"Crossref","is-referenced-by-count":3,"title":["Rituximab as a Preemptive Treatment to Prevent Recurrence of Primary Focal Segmental Glomerulosclerosis: A Novel Approach"],"prefix":"10.6002","volume":"17","author":[{"name":"From the Department of Internal Medicine and Nephrology, Cairo University, Cairo, Egypt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahier","family":"El Khashab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"El Khashab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"El Ghoneimy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Abdo","family":"AbdelRassoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4021","reference":[{"issue":"8","key":"ref0","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","article-title":"Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants","volume":"15","author":"Chun","year":"2004","unstructured":"1. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004;15(8):2169-2177.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"ref1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ndt\/gfp538","article-title":"Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation","volume":"25","author":"Ponticelli","year":"2010","unstructured":"2. Ponticelli C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant. 2010;25(1):25-31.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"ref2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00007890-199102000-00025","article-title":"Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children-a single-center experience","volume":"51","author":"Ingulli","year":"1991","unstructured":"3. Ingulli E, Tejani A. Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children-a single-center experience. Transplantation. 1991;51(2):401-405.","journal-title":"Transplantation"},{"issue":"4","key":"ref3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/ndt\/gfk005","article-title":"Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients","volume":"21","author":"Pardon","year":"2006","unstructured":"4. Pardon A, Audard V, Caillard S, et al. Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol Dial Transplant. 2006;21(4):1053-1059.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"ref4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1399-3046.2009.01261.x","article-title":"Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review","volume":"14","author":"Vinai","year":"2010","unstructured":"5. Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr Transplant. 2010;14(3):314-325.","journal-title":"Pediatr Transplant"},{"issue":"2","key":"ref5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ajt.12045","article-title":"Recent progress in the pathophysiology and treatment of FSGS recurrence","volume":"13","author":"Cravedi","year":"2013","unstructured":"6. Cravedi P, Kopp JB, Remuzzi G. Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant. 2013;13(2):266-274.","journal-title":"Am J Transplant"},{"issue":"5","key":"ref6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1600-6143.2009.02580.x","article-title":"Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study","volume":"9","author":"Canaud","year":"2009","unstructured":"7. Canaud G, Zuber J, Sberro R, et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant. 2009;9(5):1081-1086.","journal-title":"Am J Transplant"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Araya CE, Dharnidharka VR. The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J Transplant. 2011;2011:374213.","DOI":"10.1155\/2011\/374213"},{"issue":"2","key":"ref8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00467-012-2314-6","article-title":"Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis","volume":"28","author":"Kumar","year":"2013","unstructured":"9. Kumar J, Shatat IF, Skversky AL, et al. Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis. Pediatr Nephrol. 2013;28(2):333-338.","journal-title":"Pediatr Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46.","DOI":"10.1126\/scitranslmed.3002231"},{"issue":"10","key":"ref10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMc1207233","article-title":"Angiotensin antibodies and focal segmental glomerulosclerosis","volume":"368","author":"Alachkar","year":"2013","unstructured":"11. Alachkar N, Gupta G, Montgomery RA. Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med. 2013;368(10):971-973.","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Delville M, Sigdel TK, Wei C, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014;6(256):256ra136.","DOI":"10.1126\/scitranslmed.3008538"},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2249.2005.02862.x","article-title":"Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome","volume":"141","author":"Musante","year":"2005","unstructured":"13. Musante L, Candiano G, Bruschi M, et al. Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome. Clin Exp Immunol. 2005;141(3):491-499.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"ref13","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/ndt\/gfu209","article-title":"Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance","volume":"29","author":"Guitard","year":"2014","unstructured":"14. Guitard J, Hebral AL, Fakhouri F, et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant. 2014;29(11):2084-2091.","journal-title":"Nephrol Dial Transplant"},{"issue":"9950","key":"ref14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","unstructured":"15. Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384(9950):1273-1281.","journal-title":"Lancet"},{"issue":"3","key":"ref15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/TP.0000000000001160","article-title":"Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: clinical outcomes","volume":"101","author":"Garrouste","year":"2017","unstructured":"16. Garrouste C, Canaud G, Buchler M, et al. Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: clinical outcomes. Transplantation. 2017;101(3):649-656.","journal-title":"Transplantation"},{"issue":"2","key":"ref16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nrneph.2014.216","article-title":"Causes and pathogenesis of focal segmental glomerulosclerosis","volume":"11","author":"Fogo","year":"2015","unstructured":"17. Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol. 2015;11(2):76-87.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nrneph.2012.289","article-title":"Rituximab therapy in nephrotic syndrome: implications for patients' management","volume":"9","author":"Sinha","year":"2013","unstructured":"18. Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol. 2013;9(3):154-169.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"ref18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-6143.2009.02785.x","article-title":"Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients","volume":"10","author":"Kamar","year":"2010","unstructured":"19. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant. 2010;10(1):89-98.","journal-title":"Am J Transplant"},{"issue":"4","key":"ref19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2215\/CJN.05231008","article-title":"Rituximab therapy for membranous nephropathy: a systematic review","volume":"4","author":"Bomback","year":"2009","unstructured":"20. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol. 2009;4(4):734-744.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:08:11Z","timestamp":1559110091000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/archive\/2019\/17\/3\/0\/326\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5,28]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2018.0027","relation":{},"ISSN":["1304-0855"],"issn-type":[{"value":"1304-0855","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,28]]}}}